Cargando…
Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience
Limiting excessive postprandial glucose excursions is an important component of good overall glycemic control in diabetes mellitus. Pharmacokinetic studies have shown that insulin aspart, which is structurally identical to regular human insulin except for the replacement of a single proline amino ac...
Autores principales: | Hermansen, Kjeld, Bohl, Mette, Schioldan, Anne Grethe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700065/ https://www.ncbi.nlm.nih.gov/pubmed/26607485 http://dx.doi.org/10.1007/s40265-015-0500-0 |
Ejemplares similares
-
15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
por: Liebl, Andreas, et al.
Publicado: (2018) -
Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST
(®) T1)
por: Hirsch, I. B., et al.
Publicado: (2016) -
Insulin aspart in patients with gestational diabetes mellitus and pregestational diabetes mellitus
por: Deepaklal, M. C., et al.
Publicado: (2015) -
Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018) -
Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial
por: Hirsch, Irl B., et al.
Publicado: (2012)